OECD Global Anti-Corruption and Integrity Forum 2026 | Paris

The Egmont Group, represented by Executive Secretary Jerome Beaumont, attended the 2026 OECD Global Anti-Corruption and Integrity Forum in Paris. The forum provided an opportunity to highlight the role of Financial Intelligence Units (FIUs) and the Egmont Group's work in advancing anti-corruption and integrity efforts. The event covered FIU tools and practices for investigating laundering and related topics.

Egmont Group Participates in Fifth FATF Plenary, Advancing Cooperation and Training

The Egmont Group, representing Financial Intelligence Units (FIUs) worldwide, participated in the FATF Fifth Plenary meeting held in Mexico from February 9-13, 2026. The event was opened by Mexico's Secretary of Finance and Public Credit, Mr. Édgar Amador Zamora, and chaired by FATF President Ms. Elisa de Anda Madrazo. The Plenary focused on advancing international cooperation and training initiatives among FIUs to strengthen anti-money laundering and counter-terrorist financing efforts globally.

Job Opportunity: Finance and Administrative Manager, Brussels

The Egmont Group of Financial Intelligence Units published a job opportunity for a Finance and Administrative Manager position based in Brussels, with an application deadline of April 12th. The Egmont Group is a global network of 182 FIUs that facilitates exchange of financial intelligence to combat money laundering, terrorist financing, and related crimes.

RFP - Independent IT Security Audit for Egmont Group Secretariat

The Egmont Group Secretariat issued a Request for Proposals inviting qualified vendors to conduct an independent external security audit of its IT system. The audit will assess compliance with Egmont Group security, confidentiality, and access control requirements. The IT infrastructure is built on Microsoft Entra ID, Microsoft 365, and Microsoft Azure platforms.

GPC3 CAR T cells, IL-15, IL-21, ATRT, CNS rhabdoid tumors, Baylor

GPC3 CAR T cells, IL-15, IL-21, ATRT, CNS rhabdoid tumors, Baylor

Nebulized Stem Cell EVs for Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov registered a new Phase I study (NCT07515066) investigating nebulized stem cell extracellular vesicles (EVs) for treatment of idiopathic pulmonary fibrosis. The trial is listed as not yet recruiting and will evaluate safety and tolerability of the inhaled stem cell EV therapy.

Adaptive proton therapy pediatric solid tumors Hodgkin's lymphoma

ClinicalTrials.gov registered a new Phase 2 interventional study (NCT07514819) evaluating adaptive proton therapy for pediatric patients with solid tumors and Hodgkin's lymphoma. The single-arm trial will assess treatment response rates, survival outcomes, and treatment-related toxicity in pediatric oncology patients. The study is sponsored by the University of Pennsylvania and will enroll approximately 40 participants.

MR-guided adaptive stereotactic radiotherapy for endometrial cancer, Radboud University

The National Library of Medicine registered a new clinical trial (NCT07514325) on ClinicalTrials.gov studying MR-guided adaptive stereotactic radiotherapy for endometrial cancer. The single-arm study will enroll an estimated 20 participants at Radboud University Medical Center in the Netherlands to evaluate feasibility and toxicity outcomes of adaptive radiotherapy guided by MRI imaging.

Pulsed Tm:YAG vs Holmium laser kidney stone trial, NYU Langone Health

NYU Langone Health registered a new clinical trial (NCT07516106) on ClinicalTrials.gov comparing pulsed Tm:YAG laser versus Holmium laser for kidney stone treatment. The single-center randomized study will enroll approximately 100 participants and is sponsored by NYU Langone Health. The trial appears to be recruiting.

QL1706 bispecific antibody neoadjuvant trial, not recruiting

The National Library of Medicine updated ClinicalTrials.gov trial record NCT07515469 for QL1706, a bispecific antibody, to reflect a change in recruitment status from recruiting to not recruiting in a neoadjuvant treatment setting. The trial, which evaluates QL1706 as a bispecific antibody therapeutic, has modified its enrollment status. No specific enrollment numbers or timeline changes were provided in the status update.